arrow
N

Nabil Adra

indiana university bloomington
H指数:31
被引数:3,798

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prostate Cancer, Version 3.2026

前列腺癌,版本3.2026,NCCN肿瘤学临床实践指南

2025-11-012
PRE
Testicular Cancer, Version 2.2025 Featured Updates to the NCCN Guidelines

睾丸癌,版本 2.2025 NCCN 指南特色更新

2025-04-011
PRE
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma

一项I/IB期、开放标签、剂量探索研究,旨在评估帕博利珠单抗联合伏立诺他治疗晚期前列腺癌、肾癌或尿路上皮癌患者的安全性、药效学和疗效。

2025-03-270
OAAI
Abiraterone, Olaparib, or Abiraterone plus Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
2024-08-084
PRE
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

同时发生的BRCA2/SPOP突变可预测转移性去势抵抗性前列腺癌中特殊的聚 (ADP-核糖) 聚合酶抑制剂敏感性

2024-08-015
PRE
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Sitratinib联合Nivolumab治疗晚期或转移性尿路上皮癌患者的2期研究

2024-08-012
PRE
High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience

大剂量化疗和外周血干细胞移植作为原发性纵隔非精原细胞生殖细胞肿瘤的挽救疗法: 印第安纳大学的经验

CANCER
IF5.1
2024-05-202
OAAI
Prostate Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines
2024-04-0124
OA
Safety Analyses of the Phase 3 VISION Trial of [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer

[177 Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的3期视力试验的安全性分析

2024-04-015
OA
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
2024-02-015
PRE
Prostate Cancer, Version 4.2023

前列腺癌,版本4.2023

2023-10-01138
OA